NextCell Pharma

With 20 years of global pharmaceutical leadership experience and a unique dual background in molecular biology and business management, she offers valuable insight into how large pharmaceutical companies assess scientific quality, manufacturability, and commercial readiness when evaluating licensing opportunities. Angela's addition to the Board of Advisors marks an important strategic step as NextCell prepares to enter the next stage of its journey-from development to partnership. She will join Professor Per-Ola Carlsson, principal investigator of all clinical trials involving ProTrans (ProTrans-1, ProTrans-2, ProTrans-Repeat, and ProTrans-Young), and Dr. Eric Strati, PharmD, MBA, a commercial strategist with a proven track record in the successful development and launch of MSC therapies, including Alofisel and Ryoncil.

Together, these three distinguished experts form a well-rounded and complementary advisory team:

• Professor Carlsson brings deep clinical and scientific leadership from the academic and investigator perspective.
   
• Dr. Strati contributes extensive experience in market access, licensing strategy, and global commercial execution.
   
• Dr. Vollstedt adds critical insights from big pharma operations, including how manufacturing capabilities, quality systems, and scalability influence partnership potential.

"We are proud to welcome Angela to our advisory board," said Mathias Svahn, CEO of NextCell Pharma AB. "She brings a unique perspective that complements the strengths of both Per-Ola and Eric. With this team in place, we are more prepared than ever to advance ProTrans toward out-licensing and commercialisation."

ProTrans is an allogeneic mesenchymal stem cell (MSC) therapy developed to treat type 1 diabetes. It has demonstrated long-term efficacy from a single infusion, with clinical benefits including preserved insulin production, improved BMI, and stabilised blood pressure.

In early April 2025, the first administrative age group analysis of the ProTrans-Young study-comprising 30 patients aged 12-21 years-was completed and shows a positive trend toward preserving insulin production. This encouraging result strengthens our belief in ProTrans' potential and sets the stage for the next critical milestones. The younger cohort (30 patients aged 7-11 years) is currently being enrolled, with the primary endpoint analysis of the full trial expected in the second half of 2026.